Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Fallopian Tube Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Renal Cell Carcinoma|Ovarian Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Primary Peritoneal Carcinoma|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Melanoma|Unresectable Renal Cell Carcinoma
Interventions: DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Eribulin|DRUG: Fluorouracil|BIOLOGICAL: Ipilimumab|DRUG: Irinotecan Hydrochloride|DRUG: Leucovorin Calcium|BIOLOGICAL: Nivolumab|DRUG: Olaparib|DRUG: Oxaliplatin|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|DRUG: Selinexor|DRUG: Topotecan
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)